Hemostemix Inc. (CVE:HEM – Get Free Report) shares rose 31% on Friday . The company traded as high as C$0.23 and last traded at C$0.19. Approximately 480,687 shares traded hands during trading, a decline of 9% from the average daily volume of 525,664 shares. The stock had previously closed at C$0.15.
Hemostemix Price Performance
The company’s fifty day moving average is C$0.20 and its two-hundred day moving average is C$0.12. The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07. The firm has a market capitalization of C$27.69 million, a price-to-earnings ratio of -5.54 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- Upcoming IPO Stock Lockup Period, Explained
- As the Magnificent 7 Stalls, These 3 Stocks Are Gaining Momentum
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Gold’s Ascent: Can Miners and ETFs Take Investors to $3,000?
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Medtronic’s Expansion Gains Momentum—Time for a Market Shift?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
